The news that exports to the US will not restart before next year as well as the September quarter performance are sentiment dampeners.
Ankleshwar plant is the third such facility to face action
Wockhardt might be headed for another crisis, as it has come under the scanner of US health regulator.
Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.
Its Waluj manufacturing facility in Maharashtra failed to meet the good manufacturing norms prescribed by the UK drug regulator.
Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Wockhardt MD Murtaza Khorakiwala said his firm had responded to the FDA's observations but declined to give details.
Last month, the US Food and Drugs Administration had placed Wockhardt's facilities in Waluj near Aurangabad on import alert, barring supply of various products from these facilities to the US.
Since 2013, the FDA has banned around 30 Indian drug manufacturing units for various violations
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances